Bath & Body Works, Inc. (NYSE:BBWI) Receives $22.29 Consensus PT from Analysts

Bath & Body Works, Inc. (NYSE:BBWI) has earned a consensus rating of “Hold” from the eighteen brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $22.2857.

Several research firms have commented on BBWI. Barclays decreased their price objective on shares of Bath & Body Works from $23.00 to $22.00 and set an “equal weight” rating for the company in a research note on Thursday, August 27th. Citigroup raised Bath & Body Works from a “neutral” rating to a “buy” rating and set a $25.00 target price for the company in a report on Tuesday, August 18th. Robert W. Baird decreased their price target on Bath & Body Works from $25.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday, August 27th. Raymond James Financial reiterated a “market perform” rating on shares of Bath & Body Works in a report on Wednesday, May 27th. Finally, Deutsche Bank Aktiengesellschaft set a $22.00 price objective on Bath & Body Works in a research report on Thursday, August 27th.

Bath & Body Works Price Performance

BBWI opened at $19.56 on Friday. Bath & Body Works has a 1 year low of $14.27 and a 1 year high of $32.03. The company has a market capitalization of $3.94 billion, a price-to-earnings ratio of 5.09, a P/E/G ratio of 2.01 and a beta of 1.38. The firm’s fifty day moving average price is $19.98 and its two-hundred day moving average price is $19.76.

Bath & Body Works (NYSE:BBWI) last announced its earnings results on Wednesday, August 26th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.24 by $0.38. Bath & Body Works had a net margin of 10.83% and a negative return on equity of 53.48%. The company had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter in the prior year, the company posted $0.30 earnings per share. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. Bath & Body Works has set its Q3 2026 guidance at 0.070-0.120 EPS and its FY 2026 guidance at 2.600-2.800 EPS. As a group, equities analysts anticipate that Bath & Body Works will post 2.73 EPS for the current year.

Bath & Body Works Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 4th. Stockholders of record on Friday, August 21st were paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date was Friday, August 21st. Bath & Body Works’s payout ratio is presently 20.83%.

Hedge Funds Weigh In On Bath & Body Works

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada raised its position in Bath & Body Works by 92.8% in the first quarter. Royal Bank of Canada now owns 59,877 shares of the company’s stock worth $1,815,000 after acquiring an additional 28,815 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Bath & Body Works by 15.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 645,970 shares of the company’s stock worth $19,586,000 after acquiring an additional 87,529 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Bath & Body Works by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 562,757 shares of the company’s stock valued at $17,063,000 after purchasing an additional 36,684 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Bath & Body Works in the first quarter worth about $1,155,000. Finally, Geneos Wealth Management Inc. raised its position in shares of Bath & Body Works by 217.7% in the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock valued at $35,000 after purchasing an additional 801 shares during the period. 95.14% of the stock is owned by hedge funds and other institutional investors.

About Bath & Body Works

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.